Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan food effect study
NCT03863938Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) and gastric ulcer (3 arms), sponsored by HK inno.N Corporation. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 48 hours, Maximum Plasma Concentration at 48 hours and 1 more. Started Mar 2019; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)gastric ulcer
Beyond the preview
Go deeper on NCT03863938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03863938.